Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial

This study tests whether giving immunotherapy before and after radiofrequency ablation (a procedure that destroys small liver tumors with heat) improves outcomes for patients with early-stage liver cancer (hepatocellular carcinoma, or HCC). It uses two immunotherapy drugs — atezolizumab and bevacizumab. **You may be eligible if:** - You are 18 or older with a confirmed diagnosis of liver cancer (HCC) - You have 1 to 3 small liver tumors, each under 3 cm, suitable for ablation - Your liver function is adequate (Child-Pugh Class A) - Your overall health is good (ECOG performance status 0 or 1) - Your blood counts and organ function meet minimum requirements **You may NOT be eligible if:** - You have cancer that has spread outside the liver - You have had a prior liver transplant or prior HCC surgery showing blood vessel invasion - You have an active autoimmune disease requiring systemic treatment - You are on blood thinners or high-dose aspirin - You have uncontrolled hepatitis B (viral load over 500 IU/mL) - You are pregnant or breastfeeding - You have a history of HIV Talk to your doctor to see if this trial is right for you.